CTX213
In Development
CRISPR Therapeutics
Overview
A next-generation, deviceless beta-cell replacement candidate for type 1 diabetes, made of unencapsulated precursor islet cells derived from gene-edited, hypoimmune induced pluripotent stem cells (iPSCs), designed for direct administration without an encapsulation device or chronic immunosuppression.
Preclinical. Succeeds the earlier CTX211 (formerly VCTX211/VCTX210) program, whose Phase 1 data showed detectable C-peptide 12 months after implantation; that proof-of-concept informed CTX213's hypoimmune engineering. CTX213 has shown compelling preclinical efficacy via direct administration and is progressing toward the clinic, with no IND filed yet as of Q2 2026.